Search research articles
Contact Us
Filters
Showing results (171-180 of 186) with videos related to
Page
of 19
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 28, 2013
Gefitinib versus placebo in completely resected non-small-cell lung cancer: results of the NCIC CTG BR19 study
Glenwood D Goss, Chris O'Callaghan, Ian Lorimer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 11, 2017
Phase III Randomized, Placebo-Controlled, Double-Blind Trial of Celecoxib in Addition to Standard Chemotherapy for Advanced Non-Small-Cell Lung Cancer With Cyclooxygenase-2 Overexpression: CALGB 30801 (Alliance)
Martin J Edelman, Xiaofei Wang, Lydia Hodgson, et al.
International Journal of Radiation Oncology, Biology, Physics
|
April 4, 2025
American Radium Society Appropriate Use Criteria Systematic Review and Guidelines on Reirradiation for Non-Small Cell Lung Cancer Executive Summary
Charles B Simone, Arya Amini, Indrin J Chetty, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 4, 2009
Phase I and pharmacokinetic study of sorafenib in patients with hepatic or renal dysfunction: CALGB 60301
Antonius A Miller, Daryl J Murry, Kouros Owzar, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
September 23, 2024
American Radium Society Appropriate Use Criteria on Cardiac Toxicity Prevention and Management After Thoracic Radiotherapy
Arya Amini, Vlad G Zaha, Eman Hamad, et al.
Lung Cancer (Amsterdam, Netherlands)
|
March 12, 2022
Randomized phase 3 study of the anti-disialoganglioside antibody dinutuximab and irinotecan vs irinotecan or topotecan for second-line treatment of small cell lung cancer
Martin J Edelman, Mikhail Dvorkin, Konstatin Laktionov, et al.
Journal of the National Cancer Institute
|
March 19, 2013
Opportunities and challenges in the era of molecularly targeted agents and radiation therapy
Steven H Lin, Thomas J George, Edgar Ben-Josef, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
August 25, 2009
Phase 1-2a multicenter dose-ranging study of canfosfamide in combination with carboplatin and paclitaxel as first-line therapy for patients with advanced non-small cell lung cancer
Lecia V Sequist, Panos M Fidias, Jennifer S Temel, et al.
JCO Precision Oncology
|
September 7, 2023
Representativeness of Patients Enrolled in the Lung Cancer Master Protocol (Lung-MAP)
Riha Vaidya, Joseph M Unger, Lu Qian, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 1, 2025
Safety and Tolerability of Lete-cel in NSCLC-Reply
Mehmet Altan, Gilberto Lopes, T Jeroen N Hiltermann, et al.
Page
of 19
Search research articles
Search
Showing results (171-180 of 186) with videos related to
Sort By:
Page
of 19
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 28, 2013
Gefitinib versus placebo in completely resected non-small-cell lung cancer: results of the NCIC CTG BR19 study
Glenwood D Goss, Chris O'Callaghan, Ian Lorimer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 11, 2017
Phase III Randomized, Placebo-Controlled, Double-Blind Trial of Celecoxib in Addition to Standard Chemotherapy for Advanced Non-Small-Cell Lung Cancer With Cyclooxygenase-2 Overexpression: CALGB 30801 (Alliance)
Martin J Edelman, Xiaofei Wang, Lydia Hodgson, et al.
International Journal of Radiation Oncology, Biology, Physics
|
April 4, 2025
American Radium Society Appropriate Use Criteria Systematic Review and Guidelines on Reirradiation for Non-Small Cell Lung Cancer Executive Summary
Charles B Simone, Arya Amini, Indrin J Chetty, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 4, 2009
Phase I and pharmacokinetic study of sorafenib in patients with hepatic or renal dysfunction: CALGB 60301
Antonius A Miller, Daryl J Murry, Kouros Owzar, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
September 23, 2024
American Radium Society Appropriate Use Criteria on Cardiac Toxicity Prevention and Management After Thoracic Radiotherapy
Arya Amini, Vlad G Zaha, Eman Hamad, et al.
Lung Cancer (Amsterdam, Netherlands)
|
March 12, 2022
Randomized phase 3 study of the anti-disialoganglioside antibody dinutuximab and irinotecan vs irinotecan or topotecan for second-line treatment of small cell lung cancer
Martin J Edelman, Mikhail Dvorkin, Konstatin Laktionov, et al.
Journal of the National Cancer Institute
|
March 19, 2013
Opportunities and challenges in the era of molecularly targeted agents and radiation therapy
Steven H Lin, Thomas J George, Edgar Ben-Josef, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
August 25, 2009
Phase 1-2a multicenter dose-ranging study of canfosfamide in combination with carboplatin and paclitaxel as first-line therapy for patients with advanced non-small cell lung cancer
Lecia V Sequist, Panos M Fidias, Jennifer S Temel, et al.
JCO Precision Oncology
|
September 7, 2023
Representativeness of Patients Enrolled in the Lung Cancer Master Protocol (Lung-MAP)
Riha Vaidya, Joseph M Unger, Lu Qian, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 1, 2025
Safety and Tolerability of Lete-cel in NSCLC-Reply
Mehmet Altan, Gilberto Lopes, T Jeroen N Hiltermann, et al.
Page
of 19